Skip to main content

Table 2 Lung cancer stage stratified by subtypes and years

From: Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea

Lung cancer subtype

Stage

Total

P value*

NSCLC

Stage I–II

Stage III–IV

 

0.011

 2017 (Feb–Jun)

51 (42.1%)

70 (57.9%)

121

 

 2018 (Feb–Jun)

41 (33.3%)

82 (66.7%)

123

 

 2019 (Feb–Jun)

53 (37.3%)

89 (62.7%

142

 

 2020 (Feb–Jun)

37 (25.3%)

109 (74.7%)

146

 

 Total (Feb–Jun)

182 (34.2%)

350 (65.8%)

532

 

SCLC

Limited disease

Extensive disease

 

0.239

 2017 (Feb–Jun)

5 (29.4%)

12 (70.6%)

17

 

 2018 (Feb–Jun)

4 (25%)

12 (75%)

16

 

 2019 (Feb–Jun)

5 (20.8%)

19 (79.2%)

24

 

 2020 (Feb–Jun)

11 (47.8%)

12 (52.2%)

23

 

 Total (Feb–Jun)

25 (31.3%)

55 (68.8%)

80

 
  1. NSCLC non-small cell lung cancer, SCLC small cell lung cancer
  2. *Statistical significance was tested by the linear by linear association